tiprankstipranks
Trending News
More News >
Sensus Healthcare (SRTS)
NASDAQ:SRTS
Advertisement

Sensus Healthcare (SRTS) AI Stock Analysis

Compare
408 Followers

Top Page

SRTS

Sensus Healthcare

(NASDAQ:SRTS)

Rating:68Neutral
Price Target:
$5.00
▼(-11.50%Downside)
Sensus Healthcare's overall stock score is driven by strong financial performance in terms of revenue and balance sheet health, despite challenges in cash flow. Technical indicators show mixed momentum, and the high P/E ratio suggests overvaluation. The earnings call highlights potential for future growth, although immediate challenges persist.
Positive Factors
Clinical Efficacy
Positive results from a study highlight the efficacy of combining surgical excision of keloids with adjuvant Superficial Radiation Therapy (SRT) using Sensus' SRT-100, showing no keloid recurrence.
Sales Growth
Sensus anticipates surpassing 900 capital sales with expectations to reach 1,000, suggesting strong sales growth.
Trade Show Interest
Sensus Healthcare received heightened interest at key industry trade shows, acting as a catalyst for growth.
Negative Factors
Competition
SkinCure announced it would be exhibiting a fourth-generation SRT device that would compete with Sensus SRT-100 Vision image-guided SRT offering.
Revenue Decline
Total revenue was $8.3M, representing a 22% YoY decline and missing the projection of $8.7M, with a net loss of $2.6M.
Valuation Concerns
Some investors perceive Sensus and SkinCure as competitors due to similarities in their business models, potentially affecting Sensus' current valuation.

Sensus Healthcare (SRTS) vs. SPDR S&P 500 ETF (SPY)

Sensus Healthcare Business Overview & Revenue Model

Company DescriptionSensus Healthcare (SRTS) is a medical device company specializing in non-invasive treatment solutions for non-melanoma skin cancers and other dermatological conditions. The company operates in the healthcare sector, focusing on developing and providing innovative, cost-effective, and patient-friendly technologies. Its flagship product, the SRT-100, utilizes Superficial Radiation Therapy (SRT) to treat skin cancer and keloids without the need for surgery, offering a painless alternative with minimal side effects.
How the Company Makes MoneySensus Healthcare generates revenue primarily through the sale and leasing of its SRT-100 devices to dermatology clinics, hospitals, and healthcare facilities. The company also earns income from service contracts and maintenance agreements, providing ongoing support and ensuring optimal performance of their devices. Additionally, Sensus may engage in partnerships or collaborations with other healthcare providers to expand its market reach and drive sales growth. Revenue is further supplemented by training and support services offered to healthcare professionals using their technology.

Sensus Healthcare Earnings Call Summary

Earnings Call Date:May 15, 2025
(Q1-2025)
|
% Change Since: 21.24%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook for Sensus Healthcare. While there were significant highlights such as the expansion of the FDA program and increased brand visibility, the company faced challenges with a revenue decline and increased operating expenses leading to a net loss for the quarter. However, there is optimism for the remainder of 2025 with expected revenue growth from the FDA program and international expansion.
Q1-2025 Updates
Positive Updates
Expansion of Fair Deal Agreement Program
The Fair Deal Agreement (FDA) program showed a 65% increase in patient treatments from Q4 2024 to Q1 2025. This program is expected to significantly contribute to revenue in the second half of 2025, with plans to sign 3-5 additional multi-site FDA customers in 2025.
Strong Marketing and Brand Visibility
Sensus Healthcare expanded its brand visibility through participation in major industry events and targeted marketing activities, leading to a strong pipeline of new FDA opportunities.
International Expansion and Product Innovation
The company is progressing in its international strategy, attending major conferences such as ESTRO in Vienna and is set to exhibit at the Australian Academy of Dermatology Annual Meeting. Additionally, enhancements to the transdermal infusion system (TDI) are underway, with an expected FDA determination by year-end.
Negative Updates
Revenue Decline
Revenue for Q1 2025 was $8.3 million, down from $10.7 million in Q1 2024, primarily due to lower unit sales to the largest customer.
Increased Operating Expenses
Operating expenses were significantly higher compared to the previous year, with G&A expenses rising to $2.2 million from $1.6 million, and selling and marketing expenses increasing to $2.2 million from $1.3 million.
Net Loss in Q1 2025
Sensus reported a net loss of $2.6 million or $0.16 per share in Q1 2025, compared to a net income of $2.3 million or $0.14 per diluted share in Q1 2024.
Company Guidance
During the Sensus Healthcare Q1 2025 earnings call, the company reported first-quarter revenues of $8.3 million, a decrease from $10.7 million in Q1 2024, primarily due to reduced unit sales to a major customer. Despite a net loss of $2.6 million or $0.16 per share, the company outlined significant investments in sales, marketing, and R&D, with operating expenses rising to $2.2 million in G&A and $2.6 million in R&D. Sensus shipped 21 SRT systems during the quarter, increasing its installed base to over 880 units, with expectations to surpass 900 by Q2 and reach 1,000 within a year. The company highlighted a 65% increase in patient treatments from its fair deal agreements, underscoring anticipated contributions to revenue in the second half of 2025. Adjusted EBITDA was negative $2.5 million, with the company maintaining a strong cash position of $19.1 million and no debt. Sensus is optimistic about returning to profitability in the upcoming quarters as its fair deal agreements mature and contribute more significantly to revenue.

Sensus Healthcare Financial Statement Overview

Summary
Sensus Healthcare demonstrates strong revenue and profit growth with a solid balance sheet characterized by low leverage and high equity. However, challenges remain with negative free cash flow, suggesting a need for improved cash management.
Income Statement
78
Positive
Sensus Healthcare showed remarkable revenue growth of 71.3% from the previous year. The gross profit margin improved significantly to 58.4%, reflecting increased operational efficiency. Net profit margin also improved substantially to 15.9%, indicating enhanced profitability. However, the EBIT margin of 19.3% and EBITDA margin of 19.3% suggest room for improvement in controlling operating expenses.
Balance Sheet
85
Very Positive
The company maintains a strong equity position with an equity ratio of 89.8%, demonstrating financial stability. The debt-to-equity ratio is low at 0.01, indicating minimal leverage and reduced financial risk. Return on equity improved significantly to 11.9%, showcasing effective utilization of shareholder funds. Overall, the balance sheet reflects solid financial health.
Cash Flow
60
Neutral
Sensus Healthcare's free cash flow improved but remains negative, indicating potential challenges in cash management. The operating cash flow to net income ratio is negative, suggesting a need to enhance cash generation from operations. Despite these challenges, the free cash flow deficit has narrowed, showing some progress towards achieving positive cash flows.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue41.81M24.41M44.53M27.04M9.58M
Gross Profit24.43M14.06M29.63M16.99M5.25M
EBITDA8.52M79.00K14.83M4.73M-6.10M
Net Income6.65M485.00K24.24M4.12M-4.72M
Balance Sheet
Total Assets62.16M53.71M56.73M32.24M28.01M
Cash, Cash Equivalents and Short-Term Investments22.06M23.15M25.52M14.52M14.91M
Total Debt602.00K783.00K1.02M225.00K1.38M
Total Liabilities6.34M4.87M8.67M6.22M6.51M
Stockholders Equity55.83M48.84M48.07M26.02M21.50M
Cash Flow
Free Cash Flow-1.11M-2.37M-1.57M-414.00K-792.73K
Operating Cash Flow-831.00K-2.15M-1.41M-286.00K-434.18K
Investing Cash Flow-276.00K-187.00K14.84M129.00K7.03M
Financing Cash Flow15.00K-40.00K-2.43M-231.00K210.01K

Sensus Healthcare Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.65
Price Trends
50DMA
4.72
Positive
100DMA
4.66
Positive
200DMA
5.84
Negative
Market Momentum
MACD
0.03
Negative
RSI
71.62
Negative
STOCH
86.99
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Positive. The current price of 5.65 is above the 20-day moving average (MA) of 4.60, above the 50-day MA of 4.72, and below the 200-day MA of 5.84, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 71.62 is Negative, neither overbought nor oversold. The STOCH value of 86.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRTS.

Sensus Healthcare Risk Analysis

Sensus Healthcare disclosed 25 risk factors in its most recent earnings report. Sensus Healthcare reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sensus Healthcare Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$77.62M42.953.46%24.75%-61.29%
53
Neutral
$87.18M-67.86%0.34%6.20%
53
Neutral
$74.75M-113.95%8.49%6.09%
52
Neutral
$7.62B0.05-63.03%2.44%16.33%0.31%
46
Neutral
$67.66M-173.47%0.34%9.38%
44
Neutral
$63.86M-94.65%-5.86%50.76%
39
Underperform
$71.72M-104.36%-1455.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SRTS
Sensus Healthcare
5.65
-0.69
-10.88%
NSPR
InspireMD
2.44
-0.54
-18.12%
CTSO
Cytosorbents
1.00
-0.03
-2.91%
RBOT
Vicarious Surgical
13.19
5.49
71.30%
HYPR
Hyperfine
1.12
-0.03
-2.61%
ICCM
Icecure Medical
0.98
0.20
25.64%

Sensus Healthcare Corporate Events

Executive/Board ChangesShareholder Meetings
Sensus Healthcare Elects New Director at Annual Meeting
Neutral
Jun 2, 2025

At the Annual Meeting of Stockholders held on May 27, 2025, Sensus Healthcare elected Anthony Petrelli as a Class I director for a three-year term. Stockholders approved an amendment to the 2017 Incentive Plan, extending its term and increasing the share issuance limit. Additionally, the compensation of the company’s executive officers for 2024 was approved on an advisory basis, and Berkowitz Pollack Brant Advisors + CPAs, LLP was ratified as the independent registered public accountant for the fiscal year ending December 31, 2025.

The most recent analyst rating on (SRTS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Sensus Healthcare stock, see the SRTS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025